Abstract-Oxidative stress modulates angiotensin (Ang) II type 1 receptor (AT 1 R) expression and function. Ang II activates renal Na ϩ /H ϩ exchanger 3 (NHE3) to increase sodium reabsorption, but the mechanisms are still elusive. In addition, the upregulation of AT 1 R during oxidative stress could promote sodium retention and lead to an increase in blood pressure. Herein, we investigated the mechanism of Ang II-mediated, AT 1 R-dependent renal NHE3 regulation and effect of oxidative stress on AT 1 R signaling and development of hypertension. Male Sprague-Dawley rats received tap water (control) or 30 mmol/L of L-buthionine-sulfoximine, an oxidant, with and without 1 mmol/L of Tempol, an antioxidant, for 3 weeks. L-Buthionine-sulfoximine-treated rats exhibited oxidative stress and high blood pressure. Incubation of renal proximal tubules with Ang II caused significantly higher NHE3 activation in L-buthionine-sulfoximine-treated rats compared with control. The activation of NHE3 was sensitive to AT 1 R blocker and inhibitors of phospholipase C, tyrosine kinase, janus kinase 2 (Jak2), Ca 2ϩ -dependent calmodulin (CaM), and Ca 2ϩ chelator. Also, incubation of proximal tubules with Ang II caused Jak2-dependent CaM phosphorylation, which led to Jak2-CaM complex formation and increased Jak2-CaM interaction with NHE3. The activation of these signaling molecules was exaggerated in L-buthionine-sulfoximine-treated rats, whereas Tempol normalized the AT 1 R signaling. In conclusion, Ang II activates renal proximal tubular NHE3 through novel pathways that involve phospholipase C and an increase in intracellular Ca 2ϩ , Jak2, and CaM. In addition, oxidative stress exaggerates Ang II signaling, which leads to overstimulation of renal NHE3 and contributes to an increase in blood pressure. eactive oxygen species play an important role as signaling molecules in a variety of cellular responses, and sustained perturbations in redox homeostasis can result in oxidative stress leading to cardiovascular damage and cellular injury. It is reported that oxidative stress can modulate angiotensin (Ang) II type 1 receptor (AT 1 R) expression and function. 1-3 Ang II, a potent vasoconstrictor and sodium retaining hormone, via AT 1 Rs, is crucial for the regulation of sodium transport in kidney and blood pressure. 4 -6 Therefore, the upregulation of AT 1 Rs during conditions like oxidative stress could promote sodium retention and lead to development of hypertension. Consequently, normalization of AT 1 R function by antioxidant supplementation could be a useful therapeutic approach to lower blood pressure.
R
eactive oxygen species play an important role as signaling molecules in a variety of cellular responses, and sustained perturbations in redox homeostasis can result in oxidative stress leading to cardiovascular damage and cellular injury. It is reported that oxidative stress can modulate angiotensin (Ang) II type 1 receptor (AT 1 R) expression and function. [1] [2] [3] Ang II, a potent vasoconstrictor and sodium retaining hormone, via AT 1 Rs, is crucial for the regulation of sodium transport in kidney and blood pressure. 4 -6 Therefore, the upregulation of AT 1 Rs during conditions like oxidative stress could promote sodium retention and lead to development of hypertension. Consequently, normalization of AT 1 R function by antioxidant supplementation could be a useful therapeutic approach to lower blood pressure.
The AT 1 R is responsible for the Na ϩ retaining effects of Ang II in the kidney. 4 -6 The renal proximal tubules express AT 1 R on both the apical and basolateral membranes, and Ang II is delivered via the general circulation and filtration or could be locally synthesized. 4 -6 Ang II increases proximal tubular sodium transport through elevation in the activity of an amiloride-sensitive sodium hydrogen exchanger (NHE), and Ang-converting enzyme inhibitors or AT 1 R blockers have been shown to decrease proximal tubular sodium and water reabsorption. [7] [8] [9] [10] [11] The NHE3 isoform is the main transporter mediating sodium reabsorption in proximal tubules, and a wide range of evidence shows that NHE3 is regulated by Ang II. 8, 10, 12 Ang II stimulates multiple signaling pathways, including mitogen-activated protein kinases, Src family kinases, phospholipase D, and Janus kinases, which could modulate NHE3 activity. 1, [13] [14] [15] Ang II has been shown to stimulate NHE3 activity in proximal tubules but does not appear to increase the steady-state levels of NHE3 mRNA. 16 Although there is evidence for involvement of protein kinase C (PKC)-dependent and PKC-independent pathways, as well as tyrosine kinase-dependent pathways, the precise mechanism of NHE3 activation by Ang II remains unclear. 17, 18 A role for p38 and extracellular signal-regulated kinase (ERK)1/2 in Ang II-mediated regulation of NHE3 in vascular smooth muscle cells has also been suggested. 18, 19 It is reported that activation of various isoforms of NHE by mitogens including Ang II could involve Ca 2ϩ -dependent calmodulin (CaM) binding to NHE. 20, 21 Interestingly, Ang II could phosphorylate CaM and subsequently increase its binding to NHE3 via activation of several protein kinases, including Janus kinase 2 (Jak2). 20 -22 Therefore, the present study was designed to identify the role of Jak2 and CaM in Ang II-induced renal proximal tubular NHE3 activation.
The major purpose of this study is to delineate key components of a signal transduction pathway that leads to the overstimulation of proximal tubular NHE3 by Ang II during oxidative stress. Oxidative stress was induced by treating male Sprague-Dawley rats with L-buthionine-sulfoximine (BSO) for 3 weeks, and animals were studied for involvement of the Jak2-CaM pathway in Ang II-induced renal proximal tubule NHE3 stimulation.
Methods
Adult male Sprague-Dawley rats were divided into the following 4 groups: (1) control, where animals were provided with tap water; (2) BSO, where animals were provided with 30 mmol/L of BSO (Sigma); Tempol, where animals were provided with 1 mmol/L of Tempol (Sigma); and BSO plus Tempol, where animals were provided with BSO plus Tempol in tap water for 3 weeks. At the end of the treatment, rats were anesthetized with Inactin (100 mg/kg IP), and blood pressure and heart rate were recorded as detailed in the supplemental Methods section (available in the online Data Supplement at http://hyper.ahajournals.org). 23 Renal proximal tubular suspension was prepared as described previously. 23 8-Isoprostane was measured by radioimmunoassay kit (516351, Cayman), and malondialdehyde was determined by the method of Mihara and Uchiyama. 24 Protein was determined by using a bicinchoninic acid method (Thermo Fisher). The animal protocol was approved by the Institutional Animal Care and Use Committee. Phospholipase C (PLC), Na ϩ /H exchanger (NHE) 3, AT 1 R ligand binding, and immunoblotting assay are detailed in the supplemental Methods section.
Statistical Analysis
Differences between means were evaluated using ANOVA with Newman-Keuls multiple test, as appropriate. PϽ0.05 was considered statistically significant.
Results
Animals treated with BSO for 3 weeks exhibited high blood pressure and oxidative stress (please see Table S1 in the online Data Supplement). The mean blood pressure in BSO-treated rats was 27 mm Hg higher than control rats (please see Table S1 ). Tempol had no effect on blood pressure, but it attenuated the rise in blood pressure in BSO-treated rats (please see Table S1 ). The levels of oxidative markers, such as proximal tubular malondialdehyde and urinary 8-isoprotane, were significantly higher in BSOtreated rats compared with control rats (please see Table S1 ). Similar to blood pressure, Tempol had no effect on oxidative markers but rescued BSO-treated rats from oxidative stress (please see Table S1 ). Both BSO and Tempol had no effect on food and water intake (data not shown), body weight, or glomerular filtration rate (please see Table S1 ).
AT 1 R Expression and PLC Stimulation
The membrane AT 1 R expression was determined by 125 I-sarAng II binding. Animals treated with BSO showed higher ligand binding compared with control rats (please see Figure  S1A ). Tempol, per se, had no effect on 125 I-sar-Ang II membrane binding, but it normalized the ligand binding in BSO-treated rats (please see Figure S1A ). Next, we measured PLC activity to examine the functional correlate of these upregulated receptors. Incubation of renal proximal tubules with Ang II increased PLC activity, as measured in the form of IP3 accumulation, in all of the experimental groups (please see Figure S1B ). However, the response to Ang II was significantly higher in BSO-treated rats compared with control rats (please see Figure S1B ). Tempol alone had no effect on PLC activity, but it normalized Ang II response in BSO-treated rats (please see Figure S1B ). Pretreatment of tubules with the AT 1 R antagonist candesartan blocked Ang II-mediated PLC stimulation in control and BSOtreated rats (please see Figure S1C ), as well as in Tempol and BSO plus Tempol-treated rats (data not shown Ang II Stimulated Apical NHE3 Activity in Proximal Tubular Brush Border Membrane Vesicles NHE3 found in brush border membranes of renal proximal tubules is relatively insensitive to 5-(N-ethyl-Nisopropyl)amiloride. 25 Incubation of brush border membrane vesicles with Յ10 Ϫ6 M 5-(N-ethyl-N-isopropyl)amiloride failed to inhibit 22 Na ϩ uptake (data not shown), indicating that the measured NHE activity, in the present study, is attributed to NHE3 and not other 5-(N-ethyl-N-isopropyl)amiloride-sensitive NHE isoforms. NHE1 is 100 times more sensitive to the inhibitory effect of 5-(N-ethyl-Nisopropyl)amiloride, relative to its effect on the NHE3 isoform. 25 Basal NHE3 activity (nanomoles of 22 Na ϩ per milligram of protein per minute) was similar in all of the experimental groups (control: 4.3Ϯ0.5; BSO: 3.9Ϯ0.6; Tempol: 4.5Ϯ0.4; BSO plus Tempol: 4.1Ϯ0.3). Also, there was no difference in brush border membrane NHE3 protein expression in these animals (please see Figure S2A ). Incubation of proximal tubules with Ang II caused a concentrationdependent increase in NHE3 activity in all of the animal groups ( Figure 1 ). However, in BSO-treated rats, NHE3 stimulation was significantly higher than in control rats ( Figure 1 ). Tempol did not change the Ang II-mediated NHE3 activation, but it normalized the Ang II response in BSO-treated rats (Figure 1) . Preincubation of proximal tubules with AT 1 R antagonist candesartan blocked Ang II (10 pM)-mediated 22 Na ϩ uptake in both control and BSO-treated rats (please see Figure S2B ). A similar effect of candesartan was seen in Tempol and BSO plus Tempol-treated rats (data not shown).
Signaling Molecules Involved in Ang II-Mediated Apical NHE3 Stimulation
To identify the signaling pathway for Ang II-mediated NHE3 stimulation, we first used PLC inhibitors, D609 and ET-18-OCH3. As shown in Figure 2A , PLC inhibitors blocked the hormonal response in control and BSO-treated rats. Similar effects were seen in Tempol and Tempol plus BSO-treated rats (data not shown). Because PLC can activate various kinase pathways, we used the broad-spectrum serine/threonine kinase inhibitor okadaic acid and the tyrosine kinase inhibitor genistein. Preincubation of tubules with okadaic acid had no effect on Ang II-mediated NHE3 stimulation in control or BSO-treated rats ( Figure 2B ). Okadaic acid also failed to inhibit Ang II-induced Na ϩ uptake in Tempol or BSO plus Tempol-treated rats (data not shown). In addition, PKC inhibitor GF109203X also had no effect on Ang II-induced NHE3 stimulation in control, BSO-treated ( Figure  2B ), or Tempol and BSO plus Tempol-treated rats (data not shown). However, incubation of tubules with genistein, a tyrosine kinase inhibitor, abolished Ang II-mediated NHE3 stimulation in control and BSO-treated rats ( Figure 2B ), suggesting the involvement of tyrosine kinase pathways. Daidzein, an inactive genistein analog, had no effect on Ang II signaling ( Figure 2B ). Similar effects of genistein were observed in Tempol and Tempol plus BSO-treated rats (data not shown). To further follow on the tyrosine kinase pathways, we tested the role of ERK1/2 and Jak2 in the stimulation of NHE3 by Ang II. Incubation of tubules from control and BSO-treated rats with Jak2 inhibitor AG490 blocked Ang II-mediated Na ϩ uptake, whereas the ERK1/2 inhibitor UO126 had no effect ( Figure 2C ). Similar effects were observed in Tempol and BSO plus Tempol-treated rats (data not shown). It is worth noting that Ang II activated tubular EKR1/2 in all of the groups, and stimulation was higher in BSO-treated rats (data not shown). Incubation of tubules with these pharmacological compounds did not change the basal NHE3 activity in control ( 22 Na ϩ uptake, in nanomoles of 22 
Role of CaM in Ang II-Induced Apical NHE3 Stimulation
Incubation of tubules with Ang II significantly increased the Ca 2ϩ accumulation in tubules from control and BSO-treated rats ( Figure 3A) . However, the accumulation was more robust in tubules from BSO-treated rats ( Figure 3A ). Tempol-treated rats showed a response similar to controls, but Tempol mitigated the effect of BSO in BSO plus Tempol-treated rats ( Figure 3A) . Pretreatment of tubules with BAPTA-AM, a cell-permeable Ca 2ϩ chelator, prevented Ang II-mediated stimulation of NHE3 in control and BSO-treated rats ( Figure  3B ), as well as in Tempol and BSO plus Tempol-treated rats (data not shown). Interestingly, CaM inhibitors chlorpromazine, fluphenazine, W-7, ophiobolin, and calmidazolium also prevented Ang II-mediated stimulation of NHE3 in control and BSO-treated rats ( Figure 3C ). Similar effects were observed in Tempol and BSO plus Tempol-treated rats (data not shown), suggesting the involvement of Ca-CaM signaling. Next, to test the direct involvement of Ca 2ϩ , tubules were treated with calcium ionophore A23187. Elevation of Ca 2ϩ with A23187 increased NHE3 activity to a similar extent in proximal tubules from all experimental groups (please see Figure S3 ).
Role of Jak2 and CaM Interaction
Because inhibitors for both Jak2 and CaM blocked Ang II-induced NHE3 stimulation, we wanted test whether Jak2 interacts with CaM. Proximal tubules were incubated with Ang II, and homogenates were used to coimmunoprecipitate the JAK2-CaM complex with CaM antibodies, followed by immunoblotting for Jak2. Ang II significantly increased the Jak2-CaM interaction in control and BSO-treated rats, but interaction was much higher in BSO-treated rats ( Figure 4A ). Tempol alone had no effect, but it normalized the Ang II-induced Jak2-CaM interaction when given to BSO-treated rats (data not shown). The Jak2-CaM interaction was abolished by BAPTA-AM, suggesting the role of Ca 2ϩ accumulation ( Figure 4A ). Next we determined whether AT 1 R activation could increase tyrosine phosphorylation of Jak2 and CaM proteins. Interestingly, exposure of tubules to Ang II increased Jak2 and CaM tyrosine phosphorylation in control and BSO-treated rats ( Figure 4B and 4C) . The phosphorylation was higher in BSO-treated compared with control-treated rats ( Figure 4B and 4C ). Tempol and BSO plus Tempol-treated rats showed a response similar to the control group (data not shown). To identify the exact pathways for Jak2-CaM phosphorylation and interaction, we used inhibitors for these proteins. Preincubation of tubules with Jak2 inhibitor abolished Ang II-induced CaM phosphorylation, whereas CaM inhibitors failed to block Ang II-mediated Jak2 phosphorylation ( Figure 4B and 4C) . We failed to detect Jak2 and CaM phosphorylation or coimmunoprecipitation in tubular homogenates without Ang II exposure (data not shown), suggesting that phosphorylation is required for complex formation. Interestingly, BAPTA-AM blocked phosphorylation of both Jak2 and CAM in response to Ang II ( Figure 4D ). To further test the role of Ca 2ϩ in the Jak2-CaM interaction, proximal tubules were incubated with A23187, a Ca 2ϩ ionophore. A23187 significantly increased the Jak2 and CaM phosphorylation and their interaction in tubules from control and BSO-treated rats (please see Figure S4A through S4C). Basal Jak2 and CaM protein expressions were similar in control and BSO-treated rats (please see Figure S4D ). A similar effect of A23187 was seen in Tempol and Tempol plus BSO-treated rats (data not shown).
Jak2, CaM, and NHE3 Interaction
To test whether phosphorylated CaM interacts with NHE3, proximal tubules were incubated with Ang II, and brush border membrane was immunoprecipitated with NHE3 antibodies followed by immunoblotting for Jak2 and CaM proteins. As shown in Figure 5A and 5B, NHE3 coimmunoprecipitated with both Jak2 and CaM proteins in both control and BSO-treated rats, but the complex formation was significantly higher in BSO-treated rats. The response to Ang II in Tempol and BSO plus Tempol-treated was similar to control rats (data not shown). Preincubation of tubules with candesartan abolished this interaction ( Figure 5A and 5B). We failed to detect the NHE3-Jak 2-CaM interaction in brush 
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border membranes from any experimental group without previous exposure of tubules to Ang II (data not shown).
Discussion
Proximal tubular NHE3, which is responsible for 60% of transcellular sodium reabsorption in the proximal tubule, is regulated by both natriuretic and antinatriuretic hormones to maintain the sodium homeostasis and blood pressure. 26 -29 Ang II, a potent antinatriuretic hormone, activates NHE3 to increase sodium reabsorption and maintain a positive sodium balance, but the mechanisms are still elusive. 4, 5, 27, 29 We now demonstrate that, in Sprague-Dawley rats, Ang II activates proximal tubular NHE3 through novel pathways that involve PLC and an increase in intracellular Ca 2ϩ , Jak2, and CaM. In addition, during oxidative stress, which upregulates renal AT 1 Rs, Ang II signaling is exaggerated, which leads to overstimulation of NHE3 and contributes to an increase in blood pressure.
The current study expands our previous work, which shows that oxidative stress upregulates AT 1 Rs, causing overstimulation of sodium transporters, and subsequently contributes to hypertension. 1, 30 The novel aspect of this study is that it elucidates the mechanism for Ang II-mediated NHE3 stimulation. We demonstrate that, in BSO-treated rats, which exhibit oxidative stress and high blood pressure, the Ang II-induced NHE3 stimulation is significantly higher than normotensive rats. The overstimulation of NHE3 is AT 1 R specific, because it is blocked by candesartan, and also the basal activity and expression of NHE3 are similar in hypertensive and normotensive rats. In addition, Tempol, which mitigates oxidative stress and high blood pressure, also normalizes AT 1 R expression and Ang II-induced NHE3 activation. However, Tempol significantly reduced both oxidative stress and blood pressure, but it failed to completely normalize the BSO effects, probably because of its inability to normalize glutathione levels, in BSO-treated rats. 31 Nevertheless, these data confirm previous findings that oxidative stress could be an independent risk factor to the development of hypertension by exaggerating AT 1 R expression, response, and stimulation of renal sodium transporters. 1, 30, [32] [33] [34] Ang II via AT 1 Rs activates serine/threonine and tyrosine kinase pathways, both of which can regulate NHE3 activity. 1, 15, 20, 28 The serine/threonine kinases are activated via PLC stimulation, and our data show that D609 and ET-18-OCH3 (PLC inhibitors) abolished Ang II-induced NHE3 stimulation, indicating the involvement of PLC pathways. However, the stimulation of NHE3 in response to Ang II was insensitive to the nonspecific serine/threonine kinase inhibitor or PKC-specific inhibitor, thus excluding the involvement of these kinases. The role of serine/threonine kinase in Ang II-mediated renal NHE is controversial. Although some studies suggest the inhibition of protein kinase A, others have reported that PKC stimulation is involved in NHE stimulation. 17, 35 The discrepancies could be because of failure of these studies to discriminate between various NHE isoforms. The present study, which focuses primarily on proximal tubular NHE3, shows that serine/threonine kinases are not involved in Ang II-mediated regulation of this isoform. Because PLC could increase intracellular Ca 2ϩ and activate CaM, various inhibitors were used to identify their role in NHE3 stimulation. Pretreatment of cells with Ca 2ϩ chelator BAPTA-AM abolished NHE3 stimulation in response to Ang II. Similar effects were observed when proximal tubules were pretreated with various CaM inhibitors, suggesting the involvement of the PLC-Ca 2ϩ -CaM pathway in Ang II-mediated NHE3 stimulation. This is further supported by data showing that Ca 2ϩ accumulation in response to Ang II was higher in BSO-treated rats, which also showed greater NHE3 stimulation.
AT 1 R can activate tyrosine kinases, which can regulate renal sodium transporters. 1, 15 We found that tyrosine kinase inhibitor genistein, but not its inactive analog daidzein, blocked the Ang II-induced NHE3 stimulation. To identify more specific molecules involved in Ang II signaling, we used ERK1/2 inhibitor UO126 and Jak2 inhibitor AG490, both of which have been shown to modulate NHE signaling. The selective Jak2 inhibitor effectively blocked NHE3 stimulation, whereas UO126 had no effect, suggesting the involvement of Jak2, although both Jak2 and EKR1/2 were activated by Ang II. Further studies showed that incubation of proximal tubules with Ang II increased Jak2 tyrosine phosphorylation. Interestingly, Ang II also increased CaM phosphorylation, which led to complex formation between Jak2 and CaM. Tyrosine phosphorylation was essential for Jak2-CaM interaction, because nonphosphorylated Jak2 and CaM failed to coimmunoprecipitate. Next, we tested whether the phosphorylated Jak2 and CaM and the subsequent complex formation modulate the NHE3 function. Immunoprecipitation and immunoblotting studies revealed that Ang II treatment of proximal tubules causes complex formation of phosphorylated Jak2 and CaM with NHE3, and this complex formation is AT 1 dependent, because it is blocked by candesartan. Taken together, these data show that, in renal proximal tubules, Ang II causes Jak2 and CaM complex formation, which subsequently interacts with NHE3 and stimulates its activity.
To determine the exact pathway for the phosphorylation of Jak2 and CaM, the cells were treated with Jak2 and CaM inhibitors before Ang II exposure. CaM inhibitor W7 failed to block the Jak2 phosphorylation, but Jak2 inhibitor AG490 abolished CaM phosphorylation. Interestingly, the cellpermeable Ca 2ϩ chelator BAPTA-AM abolished the Ang II-mediated phosphorylation of both Jak2 and CaM. These data suggest that, although Ca 2ϩ accumulation leads to phosphorylation of both Jak2 and CaM, Jak2 activation is required for CaM phosphorylation. This is a novel finding, because the role of Ca 2ϩ in Jak2 or CaM tyrosine phosphorylation is not clear. There are reports that show that Ca 2ϩ can increase CaM and Jak2 phosphorylation in vascular smooth muscle cells. 36 However, these data are contrary to a report by Fukami et al, 37 which shows that Ca 2ϩ could decrease CaM phosphorylation in Rous sarcoma-transformed cells. Also, Ca 2ϩ via PLC-␥ has been shown to inhibit NHE3 in fibroblasts. 38 These discrepancies could be either because of a difference in the cell system used or in response to various hormones used to increase Ca 2ϩ signaling and/or isoformspecific PLC activation. Our data suggest that, in proximal tubules, Ang II increases intracellular Ca 2ϩ , causing tyrosine phosphorylation/activation of Jak2, which, in turn, phosphorylates CaM.
In addition to an increase in oxidative stress and blood pressure, the BSO-treated rats showed increased AT 1 R signaling and NHE3 stimulation in response to Ang II. The enhanced response to Ang II could be because of AT 1 R upregulation, as receptor normalization by Tempol also led to normal Ang II response in BSO-treated rats. However, it is also possible that higher oxidative stress in BSO rats directly enhanced or inhibited the activity of intermediary kinases or phosphatases, respectively. The modulation of these signaling molecules could lead to increased hormonal response and enhanced NHE3 stimulation. Therefore, in the present study we bypassed the receptor stimulation by using Ca 2ϩ ionophore A23187, which increased proximal tubular intracellular Ca 2ϩ concentration to a similar extent in both control and BSO-treated rats. It is worth noting that the basal Ca 2ϩ concentration is similar among all of the experimental groups, and only Ang II-dependent Ca 2ϩ accumulation is higher in BSO-treated rats compared with other groups. Our data show that an increase in intracellular Ca 2ϩ by A23187 caused similar activation of NHE3 in all of the groups. More importantly, incubation of tubules with A23187 increased Jak and CaM phosphorylation and complex formation to a similar extent in control and BSO-treated rats. Because these molecules are directly involved in Ang II-induced NHE3 stimulation, our data provide direct evidence that exaggerated response to Ang II during oxidative stress is because of AT 1 R upregulation. It also provides further support that increases in intracellular Ca 2ϩ are responsible for AT 1 R-dependent Jak2 and CaM phosphorylation and NHE stimulation in response to Ang II.
In conclusion, we have identified a novel pathway for Ang II-mediated NHE3 activation in renal proximal tubules. Ang II via AT 1 Rs activates PLC and increases intracellular Ca 2ϩ , which phosphorylates and activates Jak2. The activated Jak2 phosphorylates CaM, which leads to a complex formation between Jak2 and CaM. The Jak2/CaM complex interacts with NHE3 and increases tubular Na ϩ uptake. More importantly, our data show that oxidative stress upregulates AT 1 Rs, which leads to enhanced AT 1 R signaling and NHE3 stimulation. The increased NHE3 stimulation could decrease sodium excretion and subsequently lead to hypertension.
Perspectives
Both natriuretic and antinatriuretic hormones play a pivotal role in proximal tubular sodium regulation. Ang II, a predominant antinatriuretic hormone, maintains positive sodium balance both by directly activating sodium transporters and indirectly via aldosterone. The increased AT 1 R signaling could lead to sodium retention and subsequently contribute to hypertension. The present study not only identifies the novel pathways for Ang II-induced NHE3 regulation but also provides insights that oxidative stress, associated with many pathophysiological conditions, could exaggerate AT 1 R signaling and contribute to overstimulation of sodium transporters and lead to hypertension. The study also identifies the beneficial effects of antioxidants in restoring the AT 1 R signaling and ameliorating hypertension.
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